Bambusa Therapeutics Unveils Promising Phase 1 Data on BBT002 at ATS 2026 Conference

Bambusa Therapeutics Unveils Phase 1 Data at ATS 2026

On May 18, 2026, at the prestigious American Thoracic Society 2026 International Conference in Orlando, Florida, Bambusa Therapeutics, Inc., a cutting-edge biotechnology firm, shared encouraging preliminary results from their Phase 1 trial of BBT002. This next-generation bispecific antibody is engineered to target two medically validated receptors, IL-4Rα and IL-5. The findings highlight its considerable potential in treating inflammatory respiratory diseases.

Key Findings from the Phase 1 Study

Bambusa presented data that displayed BBT002’s ability to demonstrate rapid and sustained effects on key biomarkers. Significant points noted from the preliminary Phase 1 data are as follows:
1. Eosinophil Levels: A critical biomarker in airway inflammation, BBT002 achieved a profound depletion of eosinophils within the first eight weeks post-administration. This depletion indicates a promising trajectory for managing Type 2 inflammation in respiratory disorders.
2. TARC Reduction: Thymus and Activation-Regulated Chemokine (TARC) is associated with Th2 immune responses. BBT002 exhibited a dose-dependent decrease in TARC levels, showcasing its effectiveness in modulating inflammatory responses.
3. pSTAT6 Inhibition: The study revealed a complete and sustained suppression of phosphorylated STAT6 (pSTAT6) for more than eight weeks, reinforcing BBT002's impact on IL-4Rα pathway activity, integral to Type 2 inflammation.
4. Pharmacokinetics: With an impressive half-life of 29.4 days, the data suggests that BBT002 could support extended dosing intervals, allowing for potentially more convenient treatment schedules for patients.

The safety profile of BBT002 was documented to be favorable, displaying good tolerability across all dose cohorts.

Advancing Clinical Development

The ATS 2026 conference marked a significant milestone, coinciding with the announcement of the first patient being dosed in a Phase 1b/2a trial, focusing on chronic rhinosinusitis with nasal polyps (CRSwNP). This expansion indicates Bambusa's dedication to extending the reach of BBT002 beyond its applications in chronic obstructive pulmonary disease (COPD).

Dr. Thang Ho, Chief Development Officer of Bambusa Therapeutics, expressed enthusiasm about the positive preliminary findings, underscoring BBT002's ability to facilitate improved clinical outcomes relative to currently marketed therapies. The ongoing data collection from the Phase 1 trials will play a pivotal role in advancing this therapeutic candidate toward potential commercialization.

Future Directions and Upcoming Milestones

Bambusa Therapeutics is poised to present further data from the multiple ascending dose (MAD) cohorts of the Phase 1 trial at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress scheduled for June 12-15, 2026. Additional topline data from the COPD and CRSwNP studies are anticipated by the end of 2026 and the first half of 2027, respectively, indicating a busy calendar ahead for the research and development team.

Conclusion

Bambusa's commitment to innovative therapeutics has the potential to redefine treatment paradigms for patients with chronic inflammatory respiratory diseases. With multiple promising candidates like BBT001 and BBT002 under development, Bambusa is on a promising path to enhance patient care and outcomes significantly in this sphere. The initial clinical results presented at ATS 2026 bolster this vision, exemplifying the practical applicability of their bispecific antibody platform and its capacity to create impactful treatment options for unmet medical needs.